• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Prostate Imaging and Treatment

UCLA Prostate Imaging and Treatment

UCLA Prostate Imaging and Treatment
  • Back to Main Radiology
  • About Us
    • Case Studies
    • Clinical Trials
    • CME Course
    • Research Publications
  • Conditions Treated
    • Prostate Cancer
    • Benign Prostatic Hyperplasia
  • Treatments & Procedures
    • Imaging and Biopsy Services
    • Prostate Artery Embolization
    • TULSA
  • Schedule an Appointment
  • Our Expert Team
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Prostate Imaging and Treatment

About Us

About Us

About Us

  • Case Studies
    • Radiation Therapy
    • Small Volume Low Grade Disease
    • Active Surveillance
    • Example of Change to Nerve Sparing
    • Extracapsular Extension and Seminal Vesicle Invasion
    • Dynamic Contrast-Enhancement for Biochemical Failure
    • MR-Guided Targeted Biopsy
    • Benign Disease (Infertility)
  • Clinical Trials
  • CME Course
  • Research Publications
  • Case Studies
  • Clinical Trials
  • CME Course
  • Research Publications
  1. Home
  2. UCLA Prostate Imaging and Treatment
  3. About Us
  4. Clinical Trials

Clinical Trials

Share this

UCLA Prostate Imaging and Intervention is engaged in investigating new approaches to diagnosing and treating diseases and conditions.

Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer

Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer

A prospective, multi-center, single-arm study, planned in 110 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

ClinicalTrials.gov identifier: NCT02766543

Principal Investigator: Steve Raman, MD, FSAR, FSIR

RSNA Press Release: Novel MRI-Guided Ultrasound Treatment Destroys Prostate Cancer

Contact: Aniket Joglekar, 310-948-8026, [email protected]   

If interested, please check out the eligibility criteria.

 


 

Embosphere® PROstate Post Market Study (PROstate)

This study is active, but not recruiting participants.

This is a prospective, open label post market study to evaluate the long-term safety and effectiveness of prostatic artery embolization (PAE) using Embosphere Microspheres. Up to 1,000 patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be enrolled in this single arm post market study. All patients at sites who meet eligibility criteria will be offered participation. Long term effectiveness of PAE on LUTS will be evaluated by International Prostate Symptom Score (IPSS) at baseline, 3 months, 12 months, 24 months and 36 months. Safety will be assessed by evaluating treatment related adverse events at the same time points, plus at 4 weeks following embolization. Erectile function will be assessed at baseline and 12 months by Sexual Health Inventory for Men (SHIM) score. Additional treatments for refractory or recurrent LUTS due to BPH post prostatic artery embolization will also be recorded.

ClinicalTrials.gov identifier: NCT03527589

Principal Investigator: Justin McWilliams, MD, FSIR

 


 

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

This study is active, but not recruiting participants.

The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.

ClinicalTrials.gov identifier: NCT01657942

Principal Investigator: Steve Raman, MD, FSAR, FSIR


Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer (LITT)

This study is active, but not recruiting participants.

This is a pilot, feasibility/exploratory study to evaluate the safety of laser interstitial thermal therapy (LITT) using Visualase in the focal treatment of localized prostate cancer as well as to gather data for the design of future studies.

ClinicalTrials.gov identifier: NCT02224911

Principal Investigator: Steven Raman, MD, FSAR, FSIR and Pantuck Alan, MD

 

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth